Geninus

Geninus Financial Leverage

The Financial Leverage (Equity Multiplier) of Geninus (389030.KQ) as of Nov 2, 2026 is 4.32. In the previous year, Financial Leverage (Equity Multiplier) was 1.49 — a change of 190.54% (higher).

Financial Leverage

4.32

YoY

190.54%

Last updated:

Financial Leverage (Equity Multiplier) of Geninus is 2025 4.32 . Financial Leverage (Equity Multiplier) of Geninus was 2024 1.49 . It decreases by 190.54% higher compared to the previous year.

The Geninus Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
3.92 KRW
Jan 1, 2019
-5.85 KRW
Jan 1, 2020
-2.71 KRW
Jan 1, 2021
1.12 KRW
Jan 1, 2022
1.06 KRW
Jan 1, 2023
1.18 KRW
Jan 1, 2024
1.49 KRW
Jan 1, 2025
4.32 KRW
The Geninus Financial Leverage history
YEARFinancial LeverageYoY
4.32+190.54%
1.49+26.62%
1.18+10.95%
1.06-5.31%
1.12-141.30%
-2.71-53.68%
-5.85-249.07%
3.92—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Geninus Stock analysis

What does Geninus do? Geninus Inc. generates revenue through the provision of single cell analysis services and genetic testing for disease prediction to the public. The company develops and manufactures genome analysis solutions, including cancer genome analysis based on tissue biopsy, and offers personal genetic testing services. Additionally, Geninus Inc. engages in software development and a rental business as part of its product portfolio. The primary customers are individuals seeking genetic insights for health management and healthcare providers requiring advanced genomic analysis tools. The company's products include NGS-based genome analysis technology, cancer genome analysis solutions, and personal genetic testing services. These offerings target healthcare institutions, medical professionals, and consumers interested in personalized health assessments. Geninus Inc. also develops software for genomic data processing, which supports its service delivery and rental business model. Revenue streams are derived from direct sales of genome analysis solutions, service fees for single cell and cancer genome analysis, and subscriptions for software and rental services. The firm's focus on NGS technology positions it within the biotechnology sector, serving both clinical and consumer markets with a range of genomic services and products. Geninus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Geninus stock

Financial Leverage (Equity Multiplier) of Geninus is 4.32 in 2025.

Financial Leverage (Equity Multiplier) of Geninus changed from 1.49 to 4.32, representing a 190.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Geninus since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Geninus with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Geninus

All Key Metrics — Geninus